Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Alba, Emilio
• dc.contributor.author Albanell Mestres, Joan
• dc.contributor.author Haba Rodríguez, Juan de la
• dc.contributor.author Barnadas, Agustí
• dc.contributor.author Calvo, Lourdes
• dc.contributor.author Sánchez-Rovira, Pedro
• dc.contributor.author Ramos, Manuel
• dc.contributor.author Rojo, Federico
• dc.contributor.author Burgués, Octavio
• dc.contributor.author Carrasco, Eva María
• dc.contributor.author Caballero, Rosalía
• dc.contributor.author Porras, Ignacio
• dc.contributor.author Tibau, Ariadna
• dc.contributor.author Cámara, Maria del Carmen
• dc.contributor.author Lluch, Ana
• dc.date.accessioned 2021-02-09T08:42:42Z
• dc.date.available 2021-02-09T08:42:42Z
• dc.date.issued 2014
• dc.description.abstract Background: The addition of trastuzumab (T) and lapatinib (L) to neoadjuvant chemotherapy increases the pathological complete response (pCR) rate in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. We investigated the efficacy of T or L with neoadjuvant chemotherapy and specific efficacy biomarkers. Methods: Patients with stages I–III (including inflammatory) HER2-positive breast cancer were randomised to receive epirubicin (E) plus cyclophosphamide (C) × 4 cycles followed by docetaxel (D) plus either T (EC-DT) or L (EC-DL). End points included pCR (primary), clinical response, toxicity, and pCR-predictive biomarkers. Results: We randomised 102 patients to EC-DT (50) and EC-DL (52). Median age was 48, 56% were premenopausal and 58% had oestrogen receptor (ER)-positive tumours. Pathological complete response in breast was 52.1% (95% CI:38.0–66.2%) for EC-DT and 25.5% (95% CI:13.5–37.5%) for EC-DL (P=0.0065). Pathological complete response in breast and axilla was 47.9% for EC-DT and 23.5% for EC-DL (P=0.011). Grade 3–4 toxicity did not differ across treatments, except for diarrhoea (2% in EC-DT vs 13.5% in EC-DL, P=0.030). Multivariate analyses showed that treatment (P=0.036) and ER (P=0.014) were the only predictors of pCR in both groups. Conclusion: EC-DT exhibited higher efficacy and lower toxicity than EC-DL. Of the different biomarkers studied, only the absence of ER expression was associated with increased pCR.en
• dc.format.mimetype application/pdf
• dc.identifier.citation Alba E, Albanell J, de la Haba J, Barnadas A, Calvo L, Sánchez-Rovira P, Ramos M, Rojo F, Burgués O, Carrasco E, Caballero R, Porras I, Tibau A, Cámara MC, Lluch A. Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial. Br J Cancer. 2014 Mar 4;110(5):1139-47. DOI: 10.1038/bjc.2013.831
• dc.identifier.doi http://dx.doi.org/10.1038/bjc.2013.831
• dc.identifier.issn 0007-0920
• dc.identifier.uri http://hdl.handle.net/10230/46396
• dc.language.iso eng
• dc.publisher Nature Research
• dc.relation.ispartof British Journal of Cancer. 2014 Mar 4;110(5):1139-47
• dc.rights This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons AttributionNonCommercial-Share Alike 3.0 Unported License.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri https://creativecommons.org/licenses/by-nc-sa/3.0/
• dc.subject.keyword HER2-positive breast canceren
• dc.subject.keyword Lapatiniben
• dc.subject.keyword Neoadjuvanten
• dc.subject.keyword Trastuzumaben
• dc.subject.keyword Biomarkersen
• dc.title Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trialen
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion